168 related articles for article (PubMed ID: 37833260)
1. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models.
Jelicic J; Juul-Jensen K; Bukumiric Z; Roost Clausen M; Ludvigsen Al-Mashhadi A; Pedersen RS; Poulsen CB; Brown P; El-Galaly TC; Stauffer Larsen T
Blood Cancer J; 2023 Oct; 13(1):157. PubMed ID: 37833260
[TBL] [Abstract][Full Text] [Related]
2. The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy.
Isaksen KT; Galleberg R; Mastroianni MA; Rinde M; Rusten LS; Barzenje D; Ramslien F; Fluge O; Slaaen M; Meyer P; Liestol K; Smeland EB; Lingjarde OC; Holte H; Brodtkorb M
Haematologica; 2023 Sep; 108(9):2454-2466. PubMed ID: 36861406
[TBL] [Abstract][Full Text] [Related]
3. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Salas MQ; Mercadal S; Domingo Domenech E; Oliveira AC; Encuentra M; Climent F; Andrade Campos M; Aguilera C; Fernández de Sevilla A; Sureda A; González-Barca E
Leuk Lymphoma; 2020 Mar; 61(3):575-581. PubMed ID: 31684781
[TBL] [Abstract][Full Text] [Related]
4. External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Warnnissorn N; Kanitsap N; Niparuck P; Boonsakan P; Kulalert P; Limvorapitak W; Bhoopat L; Saengboon S; Chantrathammachart P; Puavilai T; Chuncharunee S
Hematology; 2022 Dec; 27(1):1237-1245. PubMed ID: 36413354
[TBL] [Abstract][Full Text] [Related]
5. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
[TBL] [Abstract][Full Text] [Related]
7. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
9. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
[TBL] [Abstract][Full Text] [Related]
10. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
[No Abstract] [Full Text] [Related]
11. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M
Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752
[TBL] [Abstract][Full Text] [Related]
12. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF;
Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
[TBL] [Abstract][Full Text] [Related]
13. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
Zhong Q; Chen H; Chen D; Qin Y; He X; Yang Y; Yang J; Liu P; Zhou S; Yang S; Zhou Y; Tang L; Chen C; Shi Y
Ann Hematol; 2024 Jan; 103(1):211-226. PubMed ID: 37861735
[TBL] [Abstract][Full Text] [Related]
15. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
Advani RH; Chen H; Habermann TM; Morrison VA; Weller EA; Fisher RI; Peterson BA; Gascoyne RD; Horning SJ; ; ;
Br J Haematol; 2010 Oct; 151(2):143-51. PubMed ID: 20735398
[TBL] [Abstract][Full Text] [Related]
16. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP
Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].
Liu W; Wang X; Zhang C; Xie Y; Lin N; Tu M; Ping L; Ying Z; Deng L; Huang H; Wu M; Sun Y; Du T; Leng X; Ding N; Zheng W; Song Y; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):269-72. PubMed ID: 27093984
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
Feng YX; Su LP
Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
[No Abstract] [Full Text] [Related]
19. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
[TBL] [Abstract][Full Text] [Related]
20. Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?
Jiang C; Ding C; Xu J; Teng Y; Chen J; Wang Z; Zhou Z
Clin Nucl Med; 2021 Jan; 46(1):1-7. PubMed ID: 33181743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]